Background: Five years of prospective clinical trials confirm that the paclitaxel drug-coated
balloon (DCB)(IN. PACT Admiral, Medtronic, Dublin, Ireland) is safe and effective to treat …

Heavily calcified lesions may be difficult to dilate adequately with conventional balloons and
stents, which causes frequent periprocedural complications and higher rates of target lesion …

Objective The aim of this study was to determine the survival of patients after use of
paclitaxel coated devices (PCX), as a recent meta-analysis of randomised trials reported …

Background: While randomized trials have demonstrated the superiority of drug-coated
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …

Importance Paclitaxel-coated peripheral devices have been associated with increased
mortality, yet this harm signal has not been replicated outside of meta-analyses of small …

Background Numerous randomised clinical trials and real-world studies have supported the
safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease …

Objectives The goal of this study was to evaluate the 5-year follow-up data of the IN. PACT
DEEP (Randomized IN. PACT Amphirion Drug-Coated Balloon [DCB] vs. Standard …

Objectives This study sought to evaluate the safety and effectiveness of the Ranger drug-
coated balloon (DCB)(paclitaxel dose density 2 μg/mm2) for treating superficial femoral …

Objectives The aim of this study was to describe physician practice patterns and examine
physician-level factors associated with the use of atherectomy during index …

Background Numerous randomised controlled trials (RCTs) have demonstrated the
superiority of paclitaxel drug-coated balloons (DCBs) over non-coated angioplasty balloons …